BioRestorative TherapiesBRTX
Market Cap: $11.4M
About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Employees: 11
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding
Funds holding: 13 [Q1] → 13 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4.7% less ownership
Funds ownership: 8.39% [Q1] → 3.68% (-4.7%) [Q2]
7% less capital invested
Capital invested by funds: $545K [Q1] → $506K (-$38.3K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Roth MKM Jonathan Aschoff 16% 1-year accuracy 3 / 19 met price target | 994%upside $18 | Buy Maintained | 14 Aug 2024 |